VANCOUVER, B.C., CANADA – Jan. 20, 2012 – Biolux Research Ltd. is pleased to announce that the European Patent Office recently communicated its intention to grant to Biolux a patent related to light therapy devices for treatment of bone disorders and biostimulation of bone and soft tissue. The patent specifically relates to Biolux’s proprietary devices for extra-oral photobiomodulation of the jaw for dental applications.

Biolux also announces the recent filings of two Patent Cooperation Treaty (PCT) patent applications for new apparatuses and methods for applying photobiomodulation, or light therapy, to orthodontic treatment and related procedures. PCT applications enable patent coverage in all countries that are parties to the treaty, which include all major orthodontic markets.

Utilizing light accelerated regeneration technology during traditional orthodontic treatment with appliances or clear retainers accelerates tooth movement and can dramatically reduce the typical treatment timelines. There are 2.5 new million orthodontic patients per year in North America, with a clear need and desire from both the patient and the orthodontist communities to significantly reduce treatment timelines and improve the quality and control of the procedures.

“We are very pleased to receive the allowance of our first patent, as it validates the significance of our light treatment technology and devices and adds value for our shareholders,” states Kevin Strange, President and CEO of Biolux. “We are committed to expanding our intellectual property portfolio, and developing our technology and products, as we believe we have the breakthrough innovations to revolutionize orthodontic treatment and associated procedures.”

About Biolux Research

Biolux Research Ltd. is a world leader in the development of innovative Light Accelerated Regeneration technology and products for use in orthodontics, implantology, and other dentistry markets. Biolux focuses on product development and clinical research, and its proprietary, patent-pending technologies have been developed to enhance clinical outcomes and dramatically reduce treatment timelines in dentistry in a safe, effective and non-invasive approach. www.bioluxresearch.com

For More Information:
Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com